MARKET

BIO

BIO

Bio Rad
NYSE

Real-time Quotes | Nasdaq Last Sale

585.68
-1.72
-0.29%
After Hours: 585.68 0 0.00% 17:20 01/21 EST
OPEN
586.91
PREV CLOSE
587.40
HIGH
596.45
LOW
579.66
VOLUME
197.62K
TURNOVER
--
52 WEEK HIGH
832.70
52 WEEK LOW
545.00
MARKET CAP
17.52B
P/E (TTM)
2.657
1D
5D
1M
3M
1Y
5Y
Life Sciences in selloff: BofA says “2021 is a tough act to follow”
Falling ~4.9% year-to-date, the healthcare sector in the S&P 500 ended the week as the second-worst performer in the broader index for the year so far. Life Sciences Tools and Services
Seekingalpha · 01/15 17:00
Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist
Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.
Zacks · 01/13 14:34
State of Alaska, Department of Revenue Buys Realty Income Corp, Bio-Rad Laboratories Inc, ...
Juneau, AK, based Investment company State of Alaska, Department of Revenue (Current Portfolio) buys Realty Income Corp, Bio-Rad Laboratories Inc, Monolithic Power Systems Inc, Prudential Financial Inc, O'Reilly Automotive Inc, sells , Change Healthcare In...
GuruFocus.com · 01/12 22:38
Shilanski & Associates, Inc. Buys Olin Corp, Coterra Energy Inc, Fortinet Inc, Sells Staar ...
Investment company Shilanski & Associates, Inc. (Current Portfolio) buys Olin Corp, Coterra Energy Inc, Fortinet Inc, Bio-Rad Laboratories Inc, Bicycle Therapeutics PLC, sells Staar Surgical Co, Celanese Corp, Reliance Steel & Aluminum Co, Huntington Bancs...
GuruFocus.com · 01/12 14:38
LIVE MARKETS-All it took was a few minutes, and the market tanked
reuters.com · 01/05 21:26
LIVE MARKETS-2022: Another positive year for stocks, but not without some indigestion
reuters.com · 01/05 19:19
LIVE MARKETS-Biggest Q4 profit gains seen in energy, materials, industrials
reuters.com · 01/05 18:29
LIVE MARKETS-2021 saw a lot less volatility in the S&P 500
LIVE MARKETS-2021 saw a lot less volatility in the S&P 500
reuters.com · 01/05 17:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIO. Analyze the recent business situations of Bio Rad through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BIO stock price target is 918.75 with a high estimate of 950.00 and a low estimate of 880.00.
High950.00
Average918.75
Low880.00
Current 585.68
EPS
Actual
Estimate
1.302.613.915.21
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 662
Institutional Holdings: 21.31M
% Owned: 71.23%
Shares Outstanding: 29.92M
TypeInstitutionsShares
Increased
169
1.19M
New
49
114.53K
Decreased
187
940.78K
Sold Out
43
239.43K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.93%
Healthcare Equipment & Supplies
-1.50%
Key Executives
Chairman/President/Chief Executive Officer/Director
Norman Schwartz
Chief Financial Officer/Executive Vice President
Ilan Daskal
Chief Operating Officer/Executive Vice President
Andrew Last
Executive Vice President/General Counsel/Secretary
Timothy Ernst
Executive Vice President
Michael Crowley
Executive Vice President
Giovanni Magni
Executive Vice President
Simon May
Executive Vice President
Dara Wright
Vice President/Treasurer
Ronald Hutton
Lead Director/Independent Director
Gregory Hinckley
Director
Alice Schwartz
Independent Director
Jeffrey Edwards
Independent Director
Melinda Litherland
Independent Director
Arnold Pinkston
No Data
  • All
  • Financials
  • Insiders
More
About BIO
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.

Webull offers kinds of Bio-Rad Laboratories, Inc. stock information, including NYSE:BIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIO stock methods without spending real money on the virtual paper trading platform.